2017 American Transplant Congress
Semi-Automated Pre-Donation Computed Topography (CT) Cortical Renal Volume to Predict Kidney Function in Live Kidney Donors 2 Years Following Donation.
Objective: To evaluate whether volume of the remnant kidney based on pre-donation CT and donor age correlates with post-donation 2-year renal function in live kidney…2017 American Transplant Congress
Belatacept Conversion for Calcineurin Inhibitor (CNI) Toxicity: Our First 100 Patients.
Intro: CNIs improve kidney transplant (KT) survival, but have significant toxicities, including graft dysfunction (GD), neurotoxicity (NT), or thrombotic microangiopathy (TMA). Belatacept is an alternative…2017 American Transplant Congress
The Value of Protocol Biopsy at Third Month After Kidney Transplant: A Single-Center Cohort Analysis.
Introduction: In spite of publications reporting higher detection of subclinical rejection (SR) with protocol biopsies in kidney transplant (KT) recipients there is no recommendation with…2017 American Transplant Congress
Comparison of the Estimated and Measured Glomerular Filtration Rate in Kidney Donor Candidates.
Nephrology, Houston Methodist Hospital, Houston, TX
Background and objectivesThe assessment of GFR in kidney donor candidates is necessary for the appropriate allocation of donor kidneys to recipients. This assessment can be…2016 American Transplant Congress
Impact of HLA-DR Compatibility on Efficacy Outcomes and Renal Function in Kidney Transplant Recipients Following Early Switch from Calcineurin Inhibitor to Everolimus: Subanalysis from the ELEVATE Study.
ELEVATE study group, Llobregat Catalunya, Spain.
Background: Human leukocyte antigen (HLA) compatibility between donor and recipient is considered an important factor for graft outcomes. Compatibility is associated with a lower incidence…2016 American Transplant Congress
Evaluation of the Major Adverse Cardiac Events Risk with Everolimus-Based Calcineurin Inhibitor Reduction or Withdrawal Regimen in Liver Transplant Recipients: 3-Year Post-Hoc Analysis of the Randomized H2304 Extension Study.
1Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharmaceuticals Corporation, East Hannover.
Purpose:Cardiovascular disease (CVD) is one of the leading causes of death in liver transplant recipients (LTxRs). Impaired glomerular filtration rate (GFR) is a risk factor…2016 American Transplant Congress
A Comprehensive Biomarker Study to Compare Tacrolimus and Mycophenolic Acid versus Half-Dose Tacrolimus and Everolimus in De Novo Kidney Transplant Patients in the Novartis US92 Study.
In this exploratory biomarker sub-study, a comprehensive combined targeted/ non-targeted metabolomics and targeted proteomics approach was used to assess potential differences between the everolimus+ low-dose…2016 American Transplant Congress
Impact of Early Calcineurin Inhibitor Withdrawal on Renal Function and Urinary Protein Excretion: 24 Month Analyses of the ELEVATE Study.
Background: Proteinuria is a biomarker which helps in predicting graft outcomes in kidney transplant recipients (KTxRs). The ELEVATE study was designed to determine whether an…2016 American Transplant Congress
Rapid Discontinuation of Prednisone (RDP) in Kidney Transplant (KTx) Recipients: 15-Year Outcomes.
PURPOSE: RDP after KTx is associated with increased early rejection; no decrease in medium‐term patient (PS) or graft survival (GS); and significantly decreased prednisone‐related side…2016 American Transplant Congress
Better Long-Term Renal Function with Lower Incidence of Acute Rejection and Lower CMV Infection in Renal Transplant Patients Treated with a Combination of Tacrolimus and Everolimus.
Surgery - Renal Transplant Unit, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction. Recent clinical trials have shown that the combination of CNIs with Everolimus (EVE) allows CNIs minimization, which may positively impact on chronic nephrotoxicity. Aim…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 27
- Next Page »